Increasing anthracyclines efficacy in Triple Negative Breast Cancer cells by disrupting cells defense mechanism and evaluating Caspase-3 as indicator for anthracyclines hematologic toxicity in breast cancer patients
Chemotherapy is the backbone of systemic treatment for triple negative breast cancer (TNBC), among which anthracyclines are important agents and represent the current standard treatment option. However, treatment failure usually happens due to the drug resistance developed by TNBC cells. Especially...
Main Author: | Luo, Man |
---|---|
Other Authors: | Lim Sierin |
Format: | Thesis-Doctor of Philosophy |
Language: | English |
Published: |
Nanyang Technological University
2020
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/136588 |
Similar Items
-
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
by: Craig Davison, et al.
Published: (2021-04-01) -
HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
by: Rania El‐Botty, et al.
Published: (2023-10-01) -
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
by: Paul B. Mullan, et al.
Published: (2019-04-01) -
Anthracyclines in the treatment of early breast cancer friend or foe?
by: Ana Tecic Vuger, et al.
Published: (2022-10-01) -
Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
by: Ariane V.S. Macedo, MD, MSc, et al.
Published: (2019-09-01)